Mechanisms of immunotherapy to wasp and bee venom

Clinical and Experimental Allergy

Volumn 41, Issue 9, 2011, Pages 1226-1234

  Ozdemir, C ^a,b   Kucuksezer, U C ^c   Akdis, M ^a   Akdis, C A ^a  

^a SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^b MARMARA UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BEE VENOM; BEE VENOM ALLERGEN; HISTAMINE; HYMENOPTERA VENOM; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4 ANTIBODY; INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; WASP VENOM; WASP VENOM ALLERGEN;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BASOPHIL; BEE VENOM ALLERGY; CELL POPULATION; CELL PROLIFERATION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; INSECT ALLERGY; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH2 CELL; VENOM IMMUNOTHERAPY; WASP VENOM ALLERGY;

ALLERGENS; ANIMALS; ANTIBODIES, NEUTRALIZING; BEE VENOMS; EPITOPES; HISTAMINE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; T-LYMPHOCYTES, REGULATORY; WASP VENOMS;

EID: 80051792906     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03812.x     Document Type: Review

References (91)

1. Freeman J. Vaccination against hay fever: report of results during the first three years. Lancet 1914; 1:1178-80.
2. Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998; 102:98-106.
3. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008; 205:2887-98.
4. Bousquet J, Muller UR, Dreborg S et al. Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy 1987; 42:401-13.
5. Bilo BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JN. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60:1339-49.
6. Blaser K, Carballido J, Faith A, Crameri R, Akdis C. Determinants and mechanisms of human immune responses to bee venom phospholipase A2. Int Arch Allergy Immunol 1998; 117:1-10.
7. Golden DB, Marsh DG, Freidhoff LR et al. Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol 1997; 100:760-6.
8. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127:18-27; quiz 28-19.
9. Jutel M, Akdis CA. T-cell subset regulation in atopy. Curr Allergy Asthma Rep 2011; 11:139-45.
10. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113:395-400.
11. Akkoc T, Akdis M, Akdis CA. Update in the mechanisms of allergen-specific immunotherapy. Allergy Asthma Immunol Res 2011; 3:11-20.
12. Basinski TM, Holzmann D, Eiwegger T et al. Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. J Allergy Clin Immunol 2009; 124:74-80, e78.
13. Zimmermann M, Koreck A, Meyer N et al. TWEAK and TNF-alpha cooperate in the induction of keratinocyte-apoptosis. J Allergy Clin Immunol 2011; 125:200-7.
14. Meyer N, Zimmermann M, Bürgler S et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol 2010; 125:858-65.
15. Akdis M. Healthy immune response to allergens: T regulatory cells and more. Curr Opin Immunol 2006; 18:738-44.
16. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004; 199:1567-75.
17. Ozdemir C, Akdis M, Akdis CA. T-cell response to allergens. Chem Immunol Allergy 2010; 95:22-44.
18. Ozdemir C, Yazi D, Gocmen I et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007; 18:508-15.
19. Akdis M. Immune tolerance in allergy. Curr Opin Immunol 2009; 21:700-7.
20. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL. Regulatory interactions between CD45RB high and CD45RB low CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994; 179:589-600.
21. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-87.
22. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193:F41-6.
23. Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42.
24. Bellinghausen I, Konig B, Bottcher I, Knop J, Saloga J. Inhibition of human allergic T-helper type 2 immune responses by induced regulatory T cells requires the combination of interleukin-10-treated dendritic cells and transforming growth factor-beta for their induction. Clin Exp Allergy 2006; 36:1546-55.
25. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64.
26. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
27. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-8.
28. Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192:303-10.
29. Ozdemir C, Akdis M, Akdis CA. T regulatory cells and their counterparts: masters of immune regulation. Clin Exp Allergy 2009; 39:626-39.
30. Palomares O, Yaman G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010; 40:1232-40.
31. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA 2008; 105:10113-8.
32. Gause WC, Urban JF, Linsley P, Lu P. Role of B7 signaling in the differentiation of naive CD4+ T cells to effector interleukin-4-producing T helper cells. Immunol Res 1995; 14:176-88.
33. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000; 192:295-302.
34. Salomon B, Lenschow DJ, Rhee L et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:431-40.
35. Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361:1001-6.
36. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157-61.
37. Muller U, Thurnheer U, Patrizzi R, Spiess J, Hoigne R. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979; 34:369-78.
38. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010: CD001186.
39. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-8.
40. Ciprandi G, Morandi F, Olcese R, Silvestri M, Tosca MA. Subcutaneous and sublingual immunotherapy and T regulatory cells: there is clinical relevance. Clin Exp Allergy 2010; 40:1578-9; author reply 1579-80.
41. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010; 126:969-75.
42. Shim JY, Kim BS, Cho SH, Min KU, Hong SJ. Allergen-specific conventional immunotherapy decreases immunoglobulin E-mediated basophil histamine releasability. Clin Exp Allergy 2003; 33:52-7.
43. Bonifazi F, Jutel M, Bilo BM, Birnbaum J, Muller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459-70.
44. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997; 99:450-3.
45. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-7.
46. Muller UR. Insect venoms. Chem Immunol Allergy 2010; 95:141-56.
47. Lesourd B, Paupe J, Thiollet M, Moulias R, Sainte-Laudy J, Scheinmann P. Hymenoptera venom immunotherapy. I. Induction of T cell-mediated immunity by honeybee venom immunotherapy: relationships with specific antibody responses. J Allergy Clin Immunol 1989; 83:563-71.
48. Tilmant L, Dessaint JP, Tsicopoulos A, Tonnel AB, Capron A. Concomitant augmentation of CD4+CD45R+ suppressor/inducer subset and diminution of CD4+CDw29+ helper/inducer subset during rush hyposensitization in hymenoptera venom allergy. Clin Exp Immunol 1989; 76:13-8.
49. Mamessier E, Birnbaum J, Dupuy P, Vervloet D, Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006; 36:704-13.
50. Botturi K, Vervloet D, Magnan A. T cells and allergens relationships: are they that specific? Clin Exp Allergy 2007; 37:1121-3.
51. Akdis CA, Akdis M, Blesken T et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996; 98:1676-83.
52. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-61.
53. Pilette C, Nouri-Aria KT, Jacobson MR et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-66.
54. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-72, 1472.e1.
55. Pereira-Santos MC, Baptista AP, Melo A et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008; 38:291-7.
56. Bussmann C, Xia J, Allam JP, Maintz L, Bieber T, Novak N. Early markers for protective mechanisms during rush venom immunotherapy. Allergy 2010; 65:1558-65.
57. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14.
58. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 31:3704-13.
59. Schuerwegh AJ, De Clerck LS, Bridts CH, Stevens WJ. Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy 2001; 31:740-6.
60. Plewako H, Wosinska K, Arvidsson M et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006; 141:346-53.
61. Dugas-Breit S, Przybilla B, Dugas M et al. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy. Clin Exp Allergy 2010; 40:643-9.
62. Siegmund R, Vogelsang H, Machnik A, Herrmann D. Surface membrane antigen alteration on blood basophils in patients with Hymenoptera venom allergy under immunotherapy. J Allergy Clin Immunol 2000; 106:1190-5.
63. Eberlein-Konig B, Ullmann S, Thomas P, Przybilla B. Tryptase and histamine release due to a sting challenge in bee venom allergic patients treated successfully or unsuccessfully with hyposensitization. Clin Exp Allergy 1995; 25:704-12.
64. Kucera P, Cvackova M, Hulikova K, Juzova O, Pachl J. Basophil activation can predict clinical sensitivity in patients after venom immunotherapy. J Investig Allergol Clin Immunol 2010; 20:110-6.
65. Jutel M, Muller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C. Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 1996; 26:1112-8.
66. Akoum H, Duez C, Vorng H et al. Early modifications of chemokine production and mRNA expression during rush venom immunotherapy. Cytokine 1998; 10:706-12.
67. Magnan A, Marin V, Mely L et al. Venom immunotherapy induces monocyte activation. Clin Exp Allergy 2001; 31:1303-9.
68. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-7.
69. Meiler F, Klunker S, Zimmermann M, Akdis CA, Akdis M. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors. Allergy 2008; 63:1455-63.
70. Carballido JM, Carballido-Perrig N, Kagi MK et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993; 150:3582-91.
71. Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132:13-24.
72. Jutel M, Akdis M, Blaser K, Akdis CA. Mechanisms of allergen specific immunotherapy - T-cell tolerance and more. Allergy 2006; 61:796-807.
73. Chen W, Jin W, Hardegen N et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198:1875-86.
74. Klunker S, Chong MM, Mantel PY et al. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med 2009; 206:2701-15.
75. Martinez-Gomez JM, Johansen P, Erdmann I, Senti G, Crameri R, Kundig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009; 150:59-65.
76. von Garnier C, Astori M, Kettner A et al. Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis. Eur J Immunol 2000; 30:1638-45.
77. Akdis CA. Immune regulation by histamine H4 receptors in skin. J Invest Dermatol 2008; 128:1615-6.
78. Jutel M, Watanabe T, Klunker S et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413:420-5.
79. Zhu Y, Michalovich D, Wu H et al. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 2001; 59:434-41.
80. Akdis CA, Jutel M, Akdis M. Regulatory effects of histamine and histamine receptor expression in human allergic immune responses. Chem Immunol Allergy 2008; 94:67-82.
81. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009; 39:1786-800.
82. Muller UR, Jutel M, Reimers A et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol 2008; 122:1001-7, e1004.
83. Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol 2001; 107:81-6.
84. Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108:1865-73.
85. Osna N, Elliott K, Khan MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001; 1:85-96.
86. Akdis CA, Blaser K. Bypassing IgE and targeting T cells for specific immunotherapy of allergy. Trends Immunol 2001; 22:175-8.
87. Crameri R, Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006; 18:761-8.
88. D'Anneo RW, Arena A, Gammeri E et al. Parietaria sublingual allergoid immunotherapy with a co-seasonal treatment schedule. Allergol Immunopathol (Madrid) 2008; 36:79-84.
89. Kahlert H, Suck R, Weber B et al. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int Arch Allergy Immunol 2008; 145:193-206.
90. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007; 119:906-9.
91. Pree I, Reisinger J, Focke M et al. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J Immunol 2007; 179:5309-16.